Work

Characterization of patients with BRCA mutated ovarian cancer who are eligible versus not eligible for PARP inhibitor maintenance therapy: exploratory analysis of the VELIA study

Year: 2021

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(21)00846-5

Authors: Elizabeth Swisher, Scott Kaufmann, Aikou Okamoto, Karina Steffensen, Michael Bookman, Kathleen Moore, Danielle Sullivan, Bruce Bach, Christine Ratajczak, Brenden Chen, Minh Dinh, Peter Ansell, Robert Coleman

Institutions: Seattle Cancer Care Alliance, University of Washington, Mayo Clinic, University of Southern Denmark, Region of Southern Denmark, Kaiser Permanente Northern California, OU Health Stephenson Cancer Center, University of Oklahoma, AbbVie (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3195725677

FWCI:

Cites:

Cited by:

Related to: 10